The Richmond company (Nasdaq: BIOA) will get a fraction of the money upfront from Novartis (NYSE: NVS) — up to $20 million, ...

KalVista has an estimated pro forma cash balance of $292.2 million, which is expected to fund its operations into the 2H of ...

The majority of Teva's business lies in generic and off-patent branded drugs and faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply ...

Psychedelics are being tested as add-ons to psychotherapy, but in trials, there's little detail about how the therapy is ...

An FDA approval of Merck’s drug clesrovimab by June would give physicians another option for protecting newborns from ...

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Tuesday after initially jumping after the company ...

We believe there is enormous opportunity for us in the animal pharmaceuticals market, as there is a significant need to deliver medications more efficiently,” Gelteq co-founder and CEO Nathan Givoni ...

Tonix Pharmaceuticals Holding said the Food and Drug Administration has accepted its application seeking approval of its TNX-102 SL product candidate for the chronic pain condition fibromyalgia.

FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review has been granted in ...

On Tuesday, November 26, the Centers for Medicare and Medicaid Services (CMS) proposed a new statutory interpretation that ... Congress defined the set of covered Part D drugs to exclude certain uses ...

Executives at a local company believe they have a quicker and less expensive path to get their new drug approved.